Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 19, Issue 4, 1997, Pages 245-251

  Kojima, Jun ^a   Nakajima, Kaori ^a   Ochiai, Mitsuru ^a   Nakayama, Kunio ^a  

^a Nikken Chemicals Co Ltd   (Japan)

Author keywords

Acetylcholinesterase; E 2020; NIK 247; Passive avoidance task; Scopolamine; Tacrine

Indexed keywords

AMIRIDINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; SCOPOLAMINE; TACRINE;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOVEMENT (PHYSIOLOGY); NONHUMAN; PASSIVE AVOIDANCE; RAT;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMINOQUINOLINES; AMNESIA; ANIMALS; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; HUMANS; INDANS; MALE; MOTOR ACTIVITY; PIPERIDINES; PSYCHOTROPIC DRUGS; RATS; RATS, WISTAR; SCOPOLAMINE; TACRINE;

EID: 0030748352     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Davies, P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 1979, 171: 319-27.
2. Whitehouse, P.J., Price, D.L., Struble, R.G. et al. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982, 215: 1237-9.
3. Drachman, D. A., Leavitt, J. Human memory and the cholinergic system. Arch Neurol 1974, 30: 113-21.
4. Ishii, Y., Kojima, J., Ikeda, N., Kawashima, K. Effect of NIK-247 on basal concentrations of extracellular acetylcholine in the cerebral cortex of conscious, freely moving rats. Jpn J Pharmacol 1994. 66: 289-93.
5. Kojima, J., Sugawara, Y., Obara, S. NIK-247 blocks voltage-dependent ionic currents in crayfish axon. Jpn J Pharmacol 1991, 57: 545-52.
6. Patocka, J., Bajagar, J., Bielavsky, J., Fusek, J. Kinetics of inhibition of cholinesterases by l,2,3,4-tetrahydro-9-aminoacridine in vitro. Coll Czech Chem Commun 1976, 41: 816-24.
7. Nielsen, J.A., Mena, E.E., Williams, I.H. et al. Correlation of brain levels of 9-amino-l,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol 1989, 173: 53-64.
8. Adem, A., Mohammed, A.K., Winblad, B. Multiple effects of tetrahydroaminoacridine on the cholinergic system: Biochemical and behavioural aspects. J Neural Transm 1990, 2: 113-28.
9. Rogers, S.L., Yamanishi, Y., Yamatsu, K. E-2020 - The pharmacology of a piperidine cholinesterase inhibitor. In: Cholinergic Basis for Alzheimer Therapy. Becker, R., Giacobini, E. (Eds.). Birkhaeuser: Boston 1991, 314-20.
10. Ueki, A., Miyoshi, K. Effects of cholinergic drugs on learning impairment in ventral globus pallidus-lexioned rats. J Neurol Sci 1989,90: 1-21.
11. Nabeshima, T., Yoshida, S., Kameyama, T. Effects of the novel compound NIK-247 on impairment of passive avoidance response in mice. Eur J Pharmacol 1988, 154: 263-70.
12. Yoshida, S., Nabeshima, T., Kinbara, K., Kameyama, T. Effects of NIK-247 on CO-induced impairment of passive avoidance in mice. Eur J Pharmacol 1992, 214: 247-52.
13. Yamamoto, T., Ohno, M., Kitajima. I. et al. Ameliorative effects of the centrally active cholinesterase inhibitor, NIK-247, on impairment of working memory in rats. Physiol Behav 1993, 53: 5-10.
14. Yoshida, S., Suzuki, N. Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tcrine and NIK-247 in rats. Eur J Pharmacol 1993, 250: 117-24.
15. Ellman, G.L., Courtney, K.D., Andres, V. Jr., Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7: 88-95.
16. 50 values and the type of inhibition for enzyme-catalyzed reactions. Biochem Med Metab Biol 1988, 40: 204-12.
17. Emmerling, M.R., Gregor, V.E., Schwarz, R.D. et al. PD-142676 (CI-1002), a novel anticholinesterase and muscarinic antagonist. Mol Neurobiol 1994, 9: 93-106.
18. Berman, H.A., Leonard, K. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinestenise. Mol Pharmacol 1991, 41: 412-8.
19. Hodge, A.S., Humphrey, D.R., Rosenberry, T.L. Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol Pharmacol 1992, 41: 937-42.
20. Nochi, S., Asakawa, N., Sato, T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl ]methylpiperidine hydrochloride (E2020). Biol Pharm Bull 1995, 18: 1145-7.
21. Wanibuchi, F., Nishida, T., Yamashita, H. et al. Characterization of a novel muscarinic receptor agonist, YM796: Comparison with cholinesterase inhibitors in in vivo pharmacological studies. Eur J Pharmacol 1994, 265: 151-8.
22. Yano, M., Kawai, H., Ishiguro, M. et al. Brain pharmacokinetics and pharmacological properties of a novel cognitive enhancer. NIK-247 (1). Jpn J Pharmacol 1996, 71(Suppl.): 101P.
23. Hsu, R.S., DiLeo, E.M., Chesson, S.M. High-performance liquid chromatography for the determination of tacrine and its metabolites in plasma. J Chromatogr 1990, 530: 170-6.
24. Telting-Diaz, M., Lunte, C.E. Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis .sampling. Pharm Res 1993, 10: 44-8.
25. Flynn, D.D., Mash, D.C. Multiple in vitro interactions with and differential in vivo regulation on muscarinic receptor subtypes by tetrahydroaminoacridine. J Pharmacol Exp Ther 1989, 250: 573-81.
26. Davenport. C.J., Monyer, H., Choi, D.W. Tetrahydroaminoacridine selectively attenuates NMDA receptor-mediated neurotoxicity. Eur J Pharmacol 1988, 154: 73-8.
27. Shannon, H.E., Peters, S.C. A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperreactivity in mice. J Pharmacol Exp Ther 1990, 255: 549-53.
28. Boast, C.A., Leventer, S., Sabb, A. et al. Biochemical and behavioral characterization of a novel cholinergic agonist, SR-95639. Pharmacol Biochem Behav 1991, 39: 287-92.